CompanyGraph
At a glance
- Depends onMidstream position: 6 outgoing, 8 incoming connections
- FinancialsAltman Z-Score 6.51: safe zone
- Interpretations3 currently firing — 3
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
770.79MUSDvs all stocks (USD)
Revenue (TTM)
206.22MUSDvs all stocks (USD)
Profit Margin
-8.10%vs Medical Devices peers
Beta
0.6700xvs all stocks
52-Week Change
4.26%vs all stocks
Market Capitalization
770.79MUSDvs all stocks (USD)
Enterprise Value
669.05MUSDvs all stocks (USD)
Forward P/E
-49.25xvs Medical Devices peers
Price to Sales (TTM)
3.74xvs Medical Devices peers
Price to Book (MRQ)
4.29xvs Medical Devices peers
Enterprise to Revenue
3.24xvs Medical Devices peers
Enterprise to EBITDA
-48.36xvs Medical Devices peers
Gross Margin
79.76%vs Medical Devices peers
Profit Margin
-8.10%vs Medical Devices peers
Operating Margin
-9.69%vs Medical Devices peers
Return on Assets (TTM)
-5.30%vs Medical Devices peers
Return on Equity (TTM)
-9.64%vs Medical Devices peers
Revenue (TTM)
206.22MUSDvs all stocks (USD)
Revenue per Share (TTM)
4.75USDUpdated Jul 19, 2026Quarterly Revenue Growth
11.20%vs Medical Devices peers
Gross Profit (TTM)
164.13MUSDvs all stocks (USD)
EBITDA (TTM)
-13.83MUSDvs all stocks (USD)
Net Income (TTM)
-16.70MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
11.20%vs Medical Devices peers
Operating Cash Flow (TTM)
1.87MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-2.65MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 19, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Medical Devices peers
Revenue
200.93MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
41.05MUSDFY2025 · Dec 31, 2025Gross Profit
159.88MUSDFY2025 · Dec 31, 2025Operating Income
-22.33MUSDvs all stocks (USD)
Pre-tax Income
-18.90MUSDFY2025 · Dec 31, 2025Net Income
-18.90MUSDFY2025 · Dec 31, 2025EBIT
-16.28MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-10.51MUSDFY2025 · Dec 31, 2025Research & Development
17.45MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
164.76MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
6.07MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
2.63MUSDFY2025 · Dec 31, 2025EPS (Basic)
-0.4400USDFY2025 · Dec 31, 2025EPS (Diluted)
-0.4400USDFY2025 · Dec 31, 2025Basic Shares Outstanding
42.96MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
42.96MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-18.90MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-397.00KUSDFY2025 · Dec 31, 2025Free Cash Flow
-8.81MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
42.24MUSDFY2025 · Dec 31, 2025Interest Paid
2.53MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-18.90MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
5.77MUSDFY2025 · Dec 31, 2025Stock-based Compensation
25.52MUSDFY2025 · Dec 31, 2025Other Non-cash Items
687.00KUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-3.03MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-1.76MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-8.68MUSDFY2025 · Dec 31, 2025Capital Expenditures
-8.41MUSDFY2025 · Dec 31, 2025Purchase of Investments
-192.53MUSDFY2025 · Dec 31, 2025Sale of Investments
205.10MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
4.16MUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
0.00USDFY2025 · Dec 31, 2025Long-term Debt Payments
0.00USDFY2025 · Dec 31, 2025Net Financing Cash Flow
0.00USDFY2025 · Dec 31, 2025Shares Outstanding
44.20MSharesUpdated Jul 19, 2026Float Shares
42.78MSharesUpdated Jul 19, 2026Shares Short
5.98MSharesUpdated Jul 19, 2026Short Ratio
10.46daysvs all stocks
Short % of Shares Outstanding
15.74%vs all stocks
% Held by Insiders
3.42%vs all stocks
% Held by Institutions
107.12%vs all stocks
Total Cash (MRQ)
144.68MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
3.26USDUpdated Jul 19, 2026Total Debt (MRQ)
42.95MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.2400xvs Medical Devices peers
Current Ratio (MRQ)
9.99xvs Medical Devices peers
Book Value per Share (MRQ)
4.05USDUpdated Jul 19, 2026Total Assets
238.56MUSDvs all stocks (USD)
Total Current Assets
216.12MUSDFY2025 · Dec 31, 2025Total Liabilities
61.02MUSDFY2025 · Dec 31, 2025Total Non-current Assets
22.44MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
35.74MUSDFY2025 · Dec 31, 2025Total Current Liabilities
25.28MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
42.24MUSDFY2025 · Dec 31, 2025Other Short-term Investments
105.58MUSDFY2025 · Dec 31, 2025Accounts Receivable
29.91MUSDFY2025 · Dec 31, 2025Inventory
33.90MUSDFY2025 · Dec 31, 2025Accounts Payable
4.63MUSDFY2025 · Dec 31, 2025Short-term Debt
944.00KUSDFY2025 · Dec 31, 2025Other Current Liabilities
879.00KUSDFY2025 · Dec 31, 2025Long-term Debt
35.74MUSDFY2025 · Dec 31, 2025Common Stock (Book)
4.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-450.26MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
177.53MUSDvs all stocks (USD)
52-Week Low
11.48USDUpdated Jul 19, 202652-Week High
21.89USDUpdated Jul 19, 202652-Week Change
4.26%vs all stocks
Beta
0.6700xvs all stocks
50-Day MA
15.43USDUpdated Jul 19, 2026200-Day MA
15.87USDUpdated Jul 19, 2026Avg 10-Day Volume
597.42KSharesUpdated Jul 19, 2026Avg 30-Day Volume
579.51KSharesUpdated Jul 19, 2026Diluted EPS (TTM)
-0.3900USDUpdated Jul 19, 2026Other Income / Expense
-20.00KUSDFY2025 · Dec 31, 20253 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Multi-Year Debt Decrease With Cash Near Total Debt And Equity
Long-term debt down in each of four years, and cash now covers most or all of what is left.
Reads
How does this company use capital?
Operating Income Growing With Multi-Year Revenue Growth
Revenue up in each of five years, with operating income up in each of four.
Reads
Revenue Growing With Receivables Growing
Revenue has risen three years, and what customers owe has risen with it.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.80Profit Margin: -0.08
Financial Health
Altman Z-Score 6.51: safe zoneNotable
Altman Z-Score: 6.51
Supply Chain
Midstream position: 6 outgoing, 8 incoming connectionsNotable
Outgoing: 6.00Incoming: 8.00
High connectivity hub: 14 industry connectionsNotable
Total Connections: 14.00
Companies that share the same coordination system — how they create, deliver, or capture value.
ChemPartner Pharmatech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Beta Bionics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Aarti Pharmalabs Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Tong Ren Tang Technologies Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Guizhou Sanli Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Chongqing Lummy Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Genomma Lab Internacional S.A.B. de C.V.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Design Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Jiangsu Jibeier Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Zevra Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Suzhou Sepax Technologies Inc.
3 interpretationsRevenue Growing With Receivables GrowingOperating Income Growing With Multi-Year Revenue GrowthMulti-Year Debt Decrease With Cash Near Total Debt And Equity
Okta Inc.
3 interpretationsRevenue Growing With Receivables GrowingOperating Income Growing With Multi-Year Revenue GrowthMulti-Year Debt Decrease With Cash Near Total Debt And Equity
Global-E Online Ltd.
2 interpretationsRevenue Growing With Receivables GrowingOperating Income Growing With Multi-Year Revenue Growth